{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:07:51Z","timestamp":1791241671019,"version":"4.1.0"},"reference-count":106,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Genetics"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.cancergen.2011.09.004","type":"journal-article","created":{"date-parts":[[2011,12,4]],"date-time":"2011-12-04T22:19:53Z","timestamp":1323037193000},"page":"525-535","source":"Crossref","is-referenced-by-count":47,"title":["Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer"],"prefix":"10.1016","volume":"204","author":[{"given":"Johanne I.","family":"Weberpals","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhuri","family":"Koti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy A.","family":"Squire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cancergen.2011.09.004_bib1","doi-asserted-by":"crossref","first-page":"7439","DOI":"10.1158\/1078-0432.CCR-04-0683","article-title":"Recurrent ovarian cancer: how important is it to treat to disease progression?","volume":"10","author":"Herzog","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cancergen.2011.09.004_bib2","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Winter","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cancergen.2011.09.004_bib3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.cancergen.2011.09.004_bib4","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1086\/301749","article-title":"Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium","volume":"62","author":"Ford","year":"1998","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.cancergen.2011.09.004_bib5","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1117679","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.cancergen.2011.09.004_bib6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.cancergen.2011.09.004_bib7","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ygyno.2010.01.010","article-title":"Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture","volume":"117","author":"Helleman","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cancergen.2011.09.004_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1755-8794-4-23","article-title":"An integrative approach to identifying cancer chemoresistance-associated pathways","volume":"4","author":"Chao","year":"2011","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.cancergen.2011.09.004_bib9","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/sj.bjc.6605031","article-title":"Molecular classification of solid tumours: towards pathway-driven therapeutics","volume":"100","author":"Swanton","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cancergen.2011.09.004_bib10","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev.pathol.4.110807.092246","article-title":"Ovarian cancer","volume":"4","author":"Cho","year":"2009","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.cancergen.2011.09.004_bib11","first-page":"932371","article-title":"Ovarian cancer pathogenesis: a model in evolution","author":"Karst","year":"2010","journal-title":"J\u00a0Oncol"},{"key":"10.1016\/j.cancergen.2011.09.004_bib12","series-title":"Tumors of the ovary and peritoneum","first-page":"119","article-title":"Tumors of the breast and female genital organs","author":"Lee","year":"2003"},{"key":"10.1016\/j.cancergen.2011.09.004_bib13","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0002-9440(10)63708-X","article-title":"Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis","volume":"164","author":"Shih","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.cancergen.2011.09.004_bib14","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jnci\/95.6.484","article-title":"Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma","volume":"95","author":"Singer","year":"2003","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cancergen.2011.09.004_bib15","first-page":"2128","article-title":"p53 mutation is a common genetic event in ovarian carcinoma","volume":"53","author":"Milner","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.cancergen.2011.09.004_bib16","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc2946","article-title":"The genesis and evolution of high-grade serous ovarian cancer","volume":"10","author":"Bowtell","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cancergen.2011.09.004_bib17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0092-8674(02)00615-3","article-title":"Cancer susceptibility and the functions of BRCA1 and BRCA2","volume":"108","author":"Venkitaraman","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.cancergen.2011.09.004_bib18","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1158\/0008-5472.CAN-09-1178","article-title":"Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma","volume":"69","author":"Sakai","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.cancergen.2011.09.004_bib19","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1158\/0008-5472.CAN-08-0088","article-title":"Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance","volume":"68","author":"Swisher","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.cancergen.2011.09.004_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/107327481101800105","article-title":"Antiangiogenic therapies in epithelial ovarian cancer","volume":"18","author":"Teoh","year":"2010","journal-title":"Cancer Control"},{"key":"10.1016\/j.cancergen.2011.09.004_bib21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ygyno.2003.12.043","article-title":"The predictive and prognostic value of serum CA 125 half-life during paclitaxel\/platinum-based chemotherapy in patients with advanced ovarian carcinoma","volume":"93","author":"Gadducci","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cancergen.2011.09.004_bib22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ygyno.2005.06.040","article-title":"Potential markers that complement expression of CA125 in epithelial ovarian cancer","volume":"99","author":"Rosen","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cancergen.2011.09.004_bib23","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.cancergen.2011.09.004_bib24","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1200\/JCO.2008.16.1703","article-title":"\u201cBRCAness\u201d syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations","volume":"26","author":"Tan","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cancergen.2011.09.004_bib25","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0002-9610(00)00460-8","article-title":"The breast surgeon\u2019s role in BRCA1 and BRCA2 testing","volume":"180","author":"Matloff","year":"2000","journal-title":"Am J Surg"},{"key":"10.1016\/j.cancergen.2011.09.004_bib26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/ng1096-185","article-title":"Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2","volume":"14","author":"Roa","year":"1996","journal-title":"Nat Genet"},{"key":"10.1016\/j.cancergen.2011.09.004_bib27","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/gcc.2870130310","article-title":"High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCAl-linked families. The Breast Cancer Linkage Consortium","volume":"13","author":"Cornelis","year":"1995","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.cancergen.2011.09.004_bib28","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0092-8674(00)81847-4","article-title":"Association of BRCA1 with RAD51 in mitotic and meiotic cells","volume":"88","author":"Scully","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.cancergen.2011.09.004_bib29","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S1097-2765(00)80466-9","article-title":"Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells","volume":"3","author":"Xu","year":"1999","journal-title":"Molecular Cell"},{"key":"10.1016\/j.cancergen.2011.09.004_bib30","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1101\/gad.14.11.1400","article-title":"Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation","volume":"14","author":"Yu","year":"2000","journal-title":"Genes Dev"},{"key":"10.1016\/j.cancergen.2011.09.004_bib31","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/ng1215","article-title":"Chromosome aberrations in solid tumors","volume":"34","author":"Albertson","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.cancergen.2011.09.004_bib32","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrm1963","article-title":"Poly(ADP-ribose): novel functions for an old molecule","volume":"7","author":"Schreiber","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.cancergen.2011.09.004_bib33","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.cancergen.2011.09.004_bib34","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of \u2018BRCAness\u2019 in sporadic cancers","volume":"4","author":"Turner","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cancergen.2011.09.004_bib35","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/jnci\/94.13.990","article-title":"Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers","volume":"94","author":"Jazaeri","year":"2002","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cancergen.2011.09.004_bib36","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1038\/sj.onc.1202086","article-title":"Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells","volume":"17","author":"Rice","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.cancergen.2011.09.004_bib37","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/bjc.2011.62","article-title":"The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer","volume":"104","author":"Sheng","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cancergen.2011.09.004_bib38","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cancergencyto.2004.12.017","article-title":"High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors","volume":"159","author":"Wilcox","year":"2005","journal-title":"Cancer Genetics Cytogenetics"},{"issue":"suppl 1","key":"10.1016\/j.cancergen.2011.09.004_bib39","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1525-1438.2006.00504.x","article-title":"BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study","volume":"16","author":"Thrall","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.cancergen.2011.09.004_bib40","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1093\/annonc\/mdq770","article-title":"Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study","volume":"22","author":"Weberpals","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cancergen.2011.09.004_bib41","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1476-4598-8-48","article-title":"Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas","volume":"8","author":"Swisher","year":"2009","journal-title":"Mol Cancer"},{"key":"10.1016\/j.cancergen.2011.09.004_bib42","doi-asserted-by":"crossref","first-page":"12117","DOI":"10.1073\/pnas.0702955104","article-title":"Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer","volume":"104","author":"Rottenberg","year":"2007","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.cancergen.2011.09.004_bib43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cancergen.2011.09.004_bib44","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1158\/1535-7163.MCT-06-0552","article-title":"Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial","volume":"6","author":"Thomas","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.cancergen.2011.09.004_bib45","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1158\/0008-5472.CAN-09-3367","article-title":"Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan","volume":"70","author":"Zander","year":"2010","journal-title":"Cancer Res"},{"issue":"suppl","key":"10.1016\/j.cancergen.2011.09.004_bib46","article-title":"Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). 2011 ASCO Annual Meeting","volume":"29","author":"Ledermann","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cancergen.2011.09.004_bib47","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.cancergen.2011.09.004_bib48","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.cancergen.2011.09.004_bib49","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/ng.569","article-title":"Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene","volume":"42","author":"Meindl","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.cancergen.2011.09.004_bib50","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4161\/cbt.8.1.7209","article-title":"PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients","volume":"8","author":"Kolasa","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.cancergen.2011.09.004_bib51","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.cancergen.2011.09.004_bib52","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/emboj.2008.61","article-title":"A\u00a0synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor","volume":"27","author":"Turner","year":"2008","journal-title":"Embo J"},{"key":"10.1016\/j.cancergen.2011.09.004_bib53","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1200\/JCO.2009.27.5719","article-title":"Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer","volume":"28","author":"Konstantinopoulos","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cancergen.2011.09.004_bib54","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/cncr.11310","article-title":"Improved survival in women with BRCA-associated ovarian carcinoma","volume":"97","author":"Cass","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.cancergen.2011.09.004_bib55","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ijc.23987","article-title":"The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer","volume":"124","author":"Weberpals","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cancergen.2011.09.004_bib56","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10549-006-9242-8","article-title":"REporting recommendations for tumor MARKer prognostic studies (REMARK)","volume":"100","author":"McShane","year":"2006","journal-title":"Breast cancer research and treatment"},{"key":"10.1016\/j.cancergen.2011.09.004_bib57","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev.pathol.4.110807.092311","article-title":"PTEN and the PI3-kinase pathway in cancer","volume":"4","author":"Chalhoub","year":"2009","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.cancergen.2011.09.004_bib58","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1158\/1078-0432.CCR-09-2990","article-title":"PI(3)king apart PTEN\u2019s role in cancer","volume":"16","author":"Zhang","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cancergen.2011.09.004_bib59","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1242\/jcs.013029","article-title":"Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer","volume":"121","author":"Astanehe","year":"2008","journal-title":"J\u00a0Cell Sci"},{"key":"10.1016\/j.cancergen.2011.09.004_bib60","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/modpathol.2010.119","article-title":"High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression","volume":"23","author":"Roh","year":"2010","journal-title":"Mod Pathol"},{"key":"10.1016\/j.cancergen.2011.09.004_bib61","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/gcc.20883","article-title":"Frequent genetic abnormalities of the PI3K\/AKT pathway in primary ovarian cancer predict patient outcome","volume":"50","author":"Huang","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.cancergen.2011.09.004_bib62","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4161\/cbt.11.1.13877","article-title":"Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer","volume":"11","author":"Tanaka","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.cancergen.2011.09.004_bib63","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/modpathol.2011.12","article-title":"Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis","volume":"24","author":"Espinosa","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.cancergen.2011.09.004_bib64","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00428-006-0346-7","article-title":"Taxol-resistance-associated gene-3 (TRAG-3\/CSAG2) expression is predictive for clinical outcome in ovarian carcinoma patients","volume":"450","author":"Materna","year":"2007","journal-title":"Virchows Arch"},{"key":"10.1016\/j.cancergen.2011.09.004_bib65","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.humpath.2008.10.019","article-title":"Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma","volume":"40","author":"Kleinberg","year":"2009","journal-title":"Hum Pathol"},{"key":"10.1016\/j.cancergen.2011.09.004_bib66","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1158\/1078-0432.CCR-06-2770","article-title":"RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model","volume":"13","author":"Mabuchi","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cancergen.2011.09.004_bib67","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ygyno.2010.10.003","article-title":"A\u00a0gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3\u2032-kinase (PI3K)\/AKT pathway in ovarian cancer cells","volume":"120","author":"Rho","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cancergen.2011.09.004_bib68","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/cm.20465","article-title":"Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression","volume":"67","author":"Karam","year":"2010","journal-title":"Cytoskeleton (Hoboken)"},{"key":"10.1016\/j.cancergen.2011.09.004_bib69","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1158\/1535-7163.MCT-10-0994","article-title":"PIK3CA mutations in patients with advanced cancers treated with PI3K\/AKT\/mTOR axis inhibitors","volume":"10","author":"Janku","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.cancergen.2011.09.004_bib70","doi-asserted-by":"crossref","first-page":"7678","DOI":"10.1158\/0008-5472.CAN-04-2933","article-title":"Mutation of the PIK3CA gene in ovarian and breast cancer","volume":"64","author":"Campbell","year":"2004","journal-title":"Cancer research"},{"key":"10.1016\/j.cancergen.2011.09.004_bib71","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/humu.9316","article-title":"PIK3CA mutations in advanced ovarian carcinomas","volume":"25","author":"Wang","year":"2005","journal-title":"Hum Mutat"},{"key":"10.1016\/j.cancergen.2011.09.004_bib72","first-page":"4639","article-title":"The Akt and ERK activation by platinum-based chemotherapy in ovarian cancer is associated with favorable patient outcome","volume":"29","author":"Ohta","year":"2009","journal-title":"Anticancer research"},{"issue":"suppl 2","key":"10.1016\/j.cancergen.2011.09.004_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000055396","article-title":"Biology of HER2 and its importance in breast cancer","volume":"61","author":"Yarden","year":"2001","journal-title":"Oncology"},{"key":"10.1016\/j.cancergen.2011.09.004_bib74","first-page":"85","article-title":"Transformational and altered signal transduction by a naturally occurring mutant EGF receptor","volume":"13","author":"Moscatello","year":"1996","journal-title":"Oncogene"},{"key":"10.1016\/j.cancergen.2011.09.004_bib75","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ygyno.2009.10.076","article-title":"Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL\/0074)","volume":"116","author":"Pautier","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cancergen.2011.09.004_bib76","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-05-0462","article-title":"Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study","volume":"11","author":"Schilder","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cancergen.2011.09.004_bib77","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/cncr.22545","article-title":"A\u00a0phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer","volume":"109","author":"Posadas","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.cancergen.2011.09.004_bib78","first-page":"568938","article-title":"Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges","author":"Siwak","year":"2010","journal-title":"J\u00a0Oncol"},{"key":"10.1016\/j.cancergen.2011.09.004_bib79","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ygyno.2010.08.008","article-title":"Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment","volume":"119","author":"Blank","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cancergen.2011.09.004_bib80","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/1078-0432.CCR-09-2308","article-title":"Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2","volume":"16","author":"Annunziata","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cancergen.2011.09.004_bib81","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1525-1438.2007.01144.x","article-title":"The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer","volume":"18","author":"Palayekar","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.cancergen.2011.09.004_bib82","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1002\/ijc.23902","article-title":"Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib","volume":"123","author":"Servidei","year":"2008","journal-title":"Int Journal Cancer"},{"key":"10.1016\/j.cancergen.2011.09.004_bib83","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature05474","article-title":"Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3","volume":"445","author":"Sergina","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.cancergen.2011.09.004_bib84","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1634\/stemcells.2005-0629","article-title":"Characterization and clinical application of human CD34+ stem\/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor","volume":"24","author":"Gordon","year":"2006","journal-title":"Stem Cells"},{"key":"10.1016\/j.cancergen.2011.09.004_bib85","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2009.22.3354","article-title":"Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer","volume":"28","author":"Makhija","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cancergen.2011.09.004_bib86","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra072067","article-title":"Epigenetics in cancer","volume":"358","author":"Esteller","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cancergen.2011.09.004_bib87","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/labinvest.2009.138","article-title":"Promoter hypermethylation of FBXO32, a novel TGF-beta\/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer","volume":"90","author":"Chou","year":"2010","journal-title":"Lab Invest"},{"key":"10.1016\/j.cancergen.2011.09.004_bib88","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1755-8794-2-34","article-title":"Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer","volume":"2","author":"Li","year":"2009","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.cancergen.2011.09.004_bib89","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1158\/1078-0432.CCR-10-3021","article-title":"Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival","volume":"17","author":"Dai","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cancergen.2011.09.004_bib90","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ygyno.2009.09.043","article-title":"Epigenetic therapies for chemoresensitization of epithelial ovarian cancer","volume":"116","author":"Matei","year":"2010","journal-title":"Gynecologic oncology"},{"key":"10.1016\/j.cancergen.2011.09.004_bib91","doi-asserted-by":"crossref","first-page":"6823","DOI":"10.1093\/nar\/gki987","article-title":"Analysis of repetitive element DNA methylation by MethyLight","volume":"33","author":"Weisenberger","year":"2005","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.cancergen.2011.09.004_bib92","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.ygyno.2005.03.023","article-title":"Demethylation of the MCJ gene in stage III\/IV epithelial ovarian cancer and response to chemotherapy","volume":"97","author":"Strathdee","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"suppl","key":"10.1016\/j.cancergen.2011.09.004_bib93","article-title":"A\u00a0phase IIa study of a sequential regimen using azacitidine to reverse platinum resistance to carboplatin in patients with platinum resistant or refractory epithelial ovarian cancer","volume":"26","author":"Bast","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cancergen.2011.09.004_bib94","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A\u00a0chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.cancergen.2011.09.004_bib95","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature02871","article-title":"The functions of animal microRNAs","volume":"431","author":"Ambros","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.cancergen.2011.09.004_bib96","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.26190","article-title":"Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of MDR1","author":"Boyerinas","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cancergen.2011.09.004_bib97","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.ygyno.2008.08.017","article-title":"Role of microRNAs in drug-resistant ovarian cancer cells","volume":"111","author":"Sorrentino","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cancergen.2011.09.004_bib98","doi-asserted-by":"crossref","first-page":"8699","DOI":"10.1158\/0008-5472.CAN-07-1936","article-title":"MicroRNA signatures in human ovarian cancer","volume":"67","author":"Iorio","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.cancergen.2011.09.004_bib99","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1158\/1078-0432.CCR-07-1731","article-title":"MicroRNA expression profiles in serous ovarian carcinoma","volume":"14","author":"Nam","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cancergen.2011.09.004_bib100","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1757-2215-2-19","article-title":"Regulation of microRNA biosynthesis and expression in 2102Ep embryonal carcinoma stem cells is mirrored in ovarian serous adenocarcinoma patients","volume":"2","author":"Gallagher","year":"2009","journal-title":"J\u00a0Ovarian Res"},{"key":"10.1016\/j.cancergen.2011.09.004_bib101","doi-asserted-by":"crossref","first-page":"e5311","DOI":"10.1371\/journal.pone.0005311","article-title":"Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries","volume":"4","author":"Wyman","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.cancergen.2011.09.004_bib102","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.biocel.2010.01.014","article-title":"MicroRNAs in ovarian cancer biology and therapy resistance","volume":"42","author":"van Jaarsveld","year":"2010","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.cancergen.2011.09.004_bib103","doi-asserted-by":"crossref","first-page":"e7314","DOI":"10.1371\/journal.pone.0007314","article-title":"MicroRNA profiling of BRCA1\/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary","volume":"4","author":"Lee","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.cancergen.2011.09.004_bib104","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1093\/carcin\/bgn172","article-title":"A\u00a0functional polymorphism in the miR-146a gene and age of familial breast\/ovarian cancer diagnosis","volume":"29","author":"Shen","year":"2008","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.cancergen.2011.09.004_bib105","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1158\/0008-5472.CAN-07-2488","article-title":"MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN","volume":"68","author":"Yang","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.cancergen.2011.09.004_bib106","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/PPO.0b013e3181bd0445","article-title":"Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development","volume":"15","author":"Tan","year":"2009","journal-title":"Cancer J"}],"container-title":["Cancer Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210776211002614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210776211002614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T07:49:06Z","timestamp":1713167346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210776211002614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":106,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S2210776211002614"],"URL":"https:\/\/doi.org\/10.1016\/j.cancergen.2011.09.004","relation":{},"ISSN":["2210-7762"],"issn-type":[{"value":"2210-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}